Currency In USD
| Previous Close | 4.08 |
| Open | 4.23 |
| Day High | 4.45 |
| Day Low | 4.2 |
| 52-Week High | 17.94 |
| 52-Week Low | 3.35 |
| Volume | 111,391 |
| Average Volume | 172,303 |
| Market Cap | 92.28M |
| PE | -1.32 |
| EPS | -3.21 |
| Moving Average 50 Days | 4.71 |
| Moving Average 200 Days | 9.45 |
| Change | 0.15 |
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
GlobeNewswire Inc.
Feb 27, 2026 9:05 PM GMT
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 13, 2026 1:00 PM GMT
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Leadership Appointments
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the